Eli Lilly and (LLY) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Eli Lilly and (LLY)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

743.02

-54.46 (-6.83%)

At close: Jan 14, 2025, 3:59 PM

747.47

0.60%

Pre-market Jan 15, 2025, 06:39 AM EST

undefined% (undefined)

Bid	741.38
Market Cap	705.36B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	9.25
PE Ratio (ttm)	80.33
Forward PE	n/a
Analyst	Buy

Ask	751
Volume	9,444,635
Avg. Volume (20D)	3,891,521
Open	784.23
Previous Close	797.48
Day's Range	729.00 - 784.23
52-Week Range	612.70 - 972.53
Beta	undefined

About LLY

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer ...

[Show more]

Industry Drug Manufacturers - General

Sector Healthcare

IPO Date Jun 1, 1972

Employees 43,000

Stock Exchange NYSE

Ticker Symbol LLY

Website https://www.lilly.com

Analyst Forecast

According to 27 analyst ratings, the average rating for LLY stock is "Buy." The 12-month stock price forecast is $1008, which is an increase of 35.66% from the latest price.

Buy 66.67%

Hold 7.41%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Eli Lilly and is scheduled to release its earnings on Feb 6, 2025, before market opens.
Analysts project revenue of $13.95B, reflecting a 49.15% YoY growth and earnings per share of 5.42, making a 117.67% increase YoY.

Why Price Moved

1 day ago · Source New

-6.59%

Eli Lily shares are trading lower after the compan... Unlock content with Pro Subscription

3 weeks ago · Source

+3.71%

Ely Lilly shares are trading higher after the FDA approved the company's Zepbound, a weight loss drug designed to treat moderate-to-severe obstructive sleep apnea in adults with obesity.

News

1 day ago · investopedia.com

Watch These Eli Lilly Price Levels as Stock Slumps on Tepid Sales Outlook

Eli Lilly (LLY) shares could remain under the microscope on Wednesday after falling sharply in trade on Tuesday as the pharmaceutical giant lowered its 2024 full-year revenue forecast.

1 day ago · seekingalpha.com

Eli Lilly and Company (LLY) CEO Dave Ricks presents at 43rd Annual J.P. Morgan Healthcare Conference (Transcript)

Eli Lilly and Company (NYSE:LLY ) 43rd Annual J.P. Morgan Healthcare Conference January 14, 2025 5:15 PM ET Company Participants Dave Ricks - Chairman and CEO Conference Call Participants Chris Schott...

17 hours ago · youtube.com

Buy the weakness in Eli Lilly, says Mizuho Healthcare Strategist Jared Holz

Jared Holz, Mizuho, joins 'Fast Money' to talk how to play Eli Lilly's stock right now.

18 hours ago · investopedia.com

S&P 500 Gains and Losses Today: Eli Lilly Stock Falls as Sales Outlook Weakens

Major U.S. equities indexes were mixed on Tuesday after the latest Producer Price Index (PPI) data showed a lighter-than-expected uptick in wholesale prices for December. The soft PPI report helped al...

19 hours ago · cnbc.com

Healthy Returns: From Eli Lilly to Amazon, here are the latest health-care deals

Companies from Johnson & Johnson to Eli Lilly, Amazon and Nvidia are announcing health-related deals at the JPMorgan Health Care Conference.

19 hours ago · zacks.com

JNJ, GSK, LLY Announce M&A Deals at JP Morgan Conference

J&J announces a big deal to acquire neuroscience company ITCI for $14.6 billion, while Lilly and GSK announce smaller deals.

21 hours ago · investopedia.com

Eli Lilly Stock Slumps on Lowered Sales Forecast

Eli Lilly (LLY) shares tumbled Tuesday after the drugmaker lowered its revenue forecast for the 2024 fiscal year.

21 hours ago · proactiveinvestors.com

Eli Lilly stumbles as weight-loss drug sales less than expected

Shares in Eli Lilly and Co fell 6.4% after the drugmaker said sales of its Mounjaro and Zepbound weight-loss medications grew more slowly than it had expected. CEO David Ricks said the US market for ...

22 hours ago · youtube.com

Final Trades: Reddit, Delta, Thermo Fisher and Eli Lilly

The Investment Committee give you their top stocks to watch for the second half.

22 hours ago · proactiveinvestors.com

Eli Lilly lowers FY revenue forecast as weight loss drug sales fall short

Shares in Eli Lilly and Co (NYSE:LLY) fell 7.3% after the drugmaker said sales of its Mounjaro and Zepbound weight-loss medications grew more slowly than it had expected. CEO David Ricks said the US m...

23 hours ago · youtube.com

Eli Lilly CEO on prospect of insurance companies covering weight loss drugs

Eli Lilly CEO David Ricks discusses the potential of insurance companies covering weight loss drugs saying they will “recognize it's the ultimate prevention medication.”

23 hours ago · fool.com

Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Dropped on Tuesday

Bad news for Eli Lilly (LLY -7.38%) stock dragged down shares of rival companies in the market for GLP-1 diet drugs on Tuesday. Lilly updated investors on its expected revenue for 2024 this morning, a...

1 day ago · invezz.com

Eli Lily cuts 2024 revenue guidance by $400M, shares sink 8%

Eli Lilly saw its shares crash in early trade on Tuesday as the pharm major provided its revenue outlook for 2024 and 2025. The pharma major cut its revenue guidance for the year leading to an around ...

1 day ago · barrons.com

Lilly's Zepbound and Mounjaro Sales Miss Estimates Again. The Wobble's Looking Serious.

It was the second consecutive miss for the two closely watched obesity and Type 2 diabetes drugs.

1 day ago · wsj.com

Eli Lilly Cuts Sales Outlook After Sluggish Growth for Incretin Drugs

Eli Lilly cut its outlook for fourth-quarter revenue citing sluggish growth in the market for incretin, which increases insulin levels.

1 day ago · youtube.com

Eli Lilly CEO David Ricks: Projecting 32% total growth for company in 2025

Eli Lilly CEO David Ricks joins 'Squawk on the Street' to discuss the company's drug pipeline, 2025 outlook, state of the weight loss drugs market, status of the weight loss drug pill, revised guidanc...

1 day ago · youtube.com

Cramer's Mad Dash: Eli Lilly

CNBC's Jim Cramer delivers his daily Mad Dash.

1 day ago · cnbc.com

Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand

Eli Lilly cut its 2024 revenue guidance, saying demand for its obesity and diabetes drugs had not met its lofty expectations. Shares dropped about 6%.

1 day ago · marketwatch.com

Mounjaro and Zepbound sales disappoint, and Eli Lilly's stock is dropping

Eli Lilly's stock was set to suffer its worst day in four years after sales of diabetes and obesity drugs Mounjaro and Zepbound missed expectations.

1 day ago · benzinga.com

Eli Lilly Cuts Q4 Revenue Guidance, Expects Around $5.5 Billion Sales From Weight Loss/Diabetes Drugs, Stock Tanks

On Tuesday, Eli Lilly and Co (NYSE: LLY) announced that it expects 2024 full-year worldwide revenue to be approximately $45.0 billion, representing a 32% growth compared to the previous year versus th...

Load More News